Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for coronary slow flow phenomenon
IRCT20251208068254N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Slow Coronary Flow (SCF) comparing Ranolazine with Placebo (2 arms). Primary endpoints: Left ventricular global longitudinal strain, Left ventricular diastolic function and 1 more. Started Jul 2026; status: completed.
02
Drugs
ranolazine
03
Conditions
Slow Coronary Flow (SCF)
Beyond the preview
Go deeper on IRCT20251208068254N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251208068254N1.